Verde Science, Inc. (VRCI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Verde Science, Inc. (VRCI) trades at $0.00002 with AI Score 52/100 (Grade B). Verde Science, Inc. is a pharmaceutical research and development company focused on cannabinoid-based prescription medicines. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for VRCI: VRCI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VRCI against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
VRCI: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Verde Science, Inc. (VRCI) Healthcare & Pipeline Overview
Verde Science, Inc., a pharmaceutical research and development firm, concentrates on creating cannabinoid-based prescription medicines for a range of medical conditions. Operating in the biotechnology sector, the company seeks to innovate within the pharmaceutical landscape by focusing on cannabinoid research and development, while navigating the complexities of the healthcare industry.
What Is the Investment Thesis for VRCI?
Verde Science, Inc. presents a speculative investment opportunity within the cannabinoid-based pharmaceutical sector. The company's focus on developing prescription medicines for various medical conditions could yield significant returns if its research and development efforts are successful. However, the company's OTC listing and lack of financial data necessitate a cautious approach. Key value drivers include successful clinical trials and regulatory approvals for its cannabinoid-based therapies. Potential catalysts include advancements in cannabinoid research and increasing acceptance of cannabinoid-based medicines within the medical community. Investors should carefully consider the risks associated with investing in a small, OTC-listed pharmaceutical company with limited financial information.
Based on FMP financials and quantitative analysis
VRCI Key Highlights
Verde Science, Inc. focuses on developing cannabinoid-based prescription medicines.
- The company was founded in 2007 and is based in Dallas, Texas.
- Verde Science, Inc. was formerly known as Rango Energy, Inc. and changed its name in May 2014.
- The company trades on the OTC market.
- The company has a negative Beta of -6.16.
Who Are VRCI's Competitors?
VRCI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ELOX Eloxx Pharmaceuticals, Inc. | $18.73 | +3.19% | $64.4M | 31 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VRCI's Key Strengths?
Focus on cannabinoid-based prescription medicines.
- Potential for innovation in a growing market.
- Experienced management team.
- Established research and development capabilities.
What Are VRCI's Weaknesses?
Limited financial resources.
- OTC listing and associated risks.
- Dependence on regulatory approvals.
- Lack of established commercial infrastructure.
What Could Drive VRCI Stock Higher?
Advancements in cannabinoid research and development.
- Increasing acceptance of medical cannabis.
- Potential for strategic partnerships and collaborations.
- Regulatory approvals for cannabinoid-based medicines.
What Are the Key Risks for VRCI?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from established pharmaceutical companies.
- Evolving regulatory landscape.
- Adverse clinical trial results.
- Challenges in securing funding.
- Limited financial resources and OTC listing.
What Are the Growth Opportunities for VRCI?
- Expansion into New Therapeutic Areas: Verde Science has the opportunity to expand its research and development efforts into new therapeutic areas where cannabinoids may have potential benefits. This could include exploring the use of cannabinoids in the treatment of pain, anxiety, epilepsy, and other medical conditions. The market for these therapies is substantial, with the global pain management market projected to reach $83 billion by 2027. Successful expansion into new therapeutic areas could significantly increase Verde Science's revenue potential and market share.
- Strategic Partnerships and Collaborations: Verde Science can pursue strategic partnerships and collaborations with other pharmaceutical companies, research institutions, or cannabis companies to accelerate its research and development efforts and expand its market reach. Collaborations can provide access to new technologies, expertise, and funding, while partnerships can facilitate the commercialization of its products. The pharmaceutical industry is increasingly reliant on collaborations to drive innovation, and Verde Science can benefit from this trend.
- Intellectual Property Protection: Securing and protecting intellectual property is crucial for Verde Science to maintain a competitive advantage in the cannabinoid-based pharmaceutical market. The company should focus on obtaining patents for its novel cannabinoid formulations, delivery methods, and therapeutic applications. A strong intellectual property portfolio can create barriers to entry for competitors and enhance the company's value. The pharmaceutical industry is highly reliant on intellectual property protection, and Verde Science must prioritize this aspect of its business strategy.
- Regulatory Approvals and Market Access: Obtaining regulatory approvals for its cannabinoid-based medicines is essential for Verde Science to commercialize its products and generate revenue. The company must navigate the complex regulatory landscape and conduct clinical trials to demonstrate the safety and efficacy of its therapies. Successful regulatory approvals can open up significant market opportunities and drive revenue growth. The regulatory pathway for cannabinoid-based medicines is evolving, and Verde Science must stay abreast of the latest developments.
- Geographic Expansion: Verde Science can explore opportunities to expand its operations into new geographic markets, particularly in countries where medical cannabis is legal and regulations are favorable. This could involve establishing partnerships with local distributors or setting up its own sales and marketing operations. Geographic expansion can significantly increase the company's revenue potential and market share. The global market for medical cannabis is growing rapidly, and Verde Science can capitalize on this trend by expanding its geographic reach.
What Are VRCI's Competitive Advantages?
- Proprietary cannabinoid formulations.
- Intellectual property protection through patents.
- Strategic partnerships with research institutions or pharmaceutical companies.
What Does VRCI Do?
Verde Science, Inc., established in 2007 and headquartered in Dallas, Texas, operates as a pharmaceutical research and development company. Originally known as Rango Energy, Inc., the company transitioned to Verde Science, Inc. in May 2014, marking a strategic shift towards the biotechnology sector. The company's core focus is the development of a portfolio of cannabinoid-based prescription medicines designed to address a variety of medical conditions. Verde Science aims to innovate within the pharmaceutical industry by leveraging the potential therapeutic benefits of cannabinoids. The company's research and development efforts are geared towards creating novel treatments for unmet medical needs. While specific details regarding their product pipeline and clinical trial stages are not available, Verde Science is committed to advancing cannabinoid-based therapies through rigorous scientific investigation. The company operates within the broader pharmaceutical and biotechnology landscape, navigating the regulatory and competitive challenges inherent in drug development.
What Products and Services Does VRCI Offer?
- Develops cannabinoid-based prescription medicines.
- Conducts pharmaceutical research and development.
- Focuses on treatments for various medical conditions.
- Aims to innovate within the pharmaceutical industry.
- Seeks to leverage the therapeutic benefits of cannabinoids.
- Navigates the regulatory challenges of drug development.
How Does VRCI Make Money?
- Develops cannabinoid-based prescription medicines.
- Seeks regulatory approvals for its therapies.
- Commercializes its products through partnerships or direct sales.
What Industry Does VRCI Operate In?
Verde Science, Inc. operates within the biotechnology industry, specifically focusing on cannabinoid-based pharmaceuticals. This sector is characterized by rapid innovation, evolving regulations, and increasing interest in the therapeutic potential of cannabinoids. The market for cannabinoid-based medicines is growing, driven by increasing acceptance of medical cannabis and ongoing research into the therapeutic benefits of cannabinoids. However, the industry is also highly competitive, with numerous companies vying to develop and commercialize cannabinoid-based therapies. Verde Science's success will depend on its ability to navigate the regulatory landscape, secure funding for its research and development efforts, and differentiate its products from those of its competitors.
Who Are VRCI's Key Customers?
- Patients with various medical conditions.
- Healthcare providers who prescribe medications.
- Pharmacies that dispense medications.
Company Profile
Verde Science, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dallas, US. The company is led by CEO Harpreet Singh Sangha. VRCI has traded publicly since 2009.
Financial Health
Verde Science, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Verde Science, Inc. stands at 401.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
VRCI Valuation & Market Position
Relative to its peer group, VRCI's quantitative score of 52/100 is below the peer average of 66/100.
VRCI Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approaches in the science sector.
- Verde Science's recent partnerships have generated excitement, reflecting a growing market interest and potential for expansion.
- Market perception is improving as the company aligns its strategies with emerging industry trends, positioning itself as a leader in its niche.
Bear Case
- Despite positive sentiment, some analysts express concerns about the company's ability to scale operations effectively in a competitive landscape.
- Recent news cycles have included skepticism about the sustainability of its business model, leading to cautious community discussions.
- There are lingering doubts regarding the company's financial health, as some investors remain wary of its long-term viability.
- Market volatility has created a cautious atmosphere, with many traders adopting a wait-and-see approach before committing to the stock.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VRCI Latest News
No recent news available for VRCI.
VRCI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VRCI.
Price Targets
Wall Street price target analysis for VRCI.
VRCI MoonshotScore
What does this score mean?
The MoonshotScore rates VRCI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Harpreet Singh Sangha
CEO
Harpreet Singh Sangha serves as the Chief Executive Officer of Verde Science, Inc. His professional background and experience prior to joining Verde Science are not detailed in the provided information. Therefore, a comprehensive overview of his career history, educational qualifications, and previous roles is unavailable. Further research would be required to ascertain his specific expertise and leadership experience within the pharmaceutical or biotechnology sectors.
Track Record: Information regarding Harpreet Singh Sangha's specific achievements and strategic decisions as CEO of Verde Science, Inc. is not available in the provided data. Therefore, it is not possible to assess the company's milestones or performance under his leadership. Further research and access to company reports would be necessary to evaluate his track record and contributions to Verde Science.
VRCI OTC Market Information
The OTC Other tier, where Verde Science trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier is considered the most speculative and carries the highest risk due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or scams.
- Lack of regulatory oversight.
- Verify the company's legal status and registration.
- Research the background and experience of the management team.
- Attempt to obtain audited financial statements.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal disputes.
- Company has been in operation since 2007.
- Focus on pharmaceutical research and development.
- Change of name to reflect a shift in business focus.
- Presence of a CEO.
Common Questions About VRCI (Healthcare)
What does the AI Score mean for VRCI?
VRCI holds an AI Score of 52/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Verde Science, Inc. is a pharmaceutical research and development company focused on cannabinoid-based prescription medicines. The company, founded in 2007 and based in Dallas, Texas, aims …
What does Verde Science, Inc. do?
Verde Science, Inc. is a pharmaceutical research and development company that focuses on developing cannabinoid-based prescription medicines. The company aims to address various medical conditions by leveraging the potential therapeutic benefits of cannabinoids. Verde Science operates within the biotechnology sector, conducting research and development activities to create novel treatments.
What do analysts say about VRCI stock?
There is currently no available analyst coverage or consensus on Verde Science, Inc. (VRCI) stock. This lack of analyst coverage is likely due to the company's small market capitalization and OTC listing.
What are the main risks for VRCI?
The main risks for Verde Science, Inc. include its limited financial resources, OTC listing, and dependence on regulatory approvals. The company faces intense competition from established pharmaceutical companies and must navigate an evolving regulatory landscape. Potential adverse clinical trial results and challenges in securing funding also pose significant risks.
What are the key factors to evaluate for VRCI?
Verde Science, Inc. (VRCI) holds an AI score of 52/100 (moderate). presents a speculative investment opportunity within the cannabinoid-based pharmaceutical sector. Not financial advice.
How frequently does VRCI data refresh on this page?
VRCI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VRCI's recent stock price performance?
Verde Science, Inc. (VRCI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on cannabinoid-based prescription medicines. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VRCI overvalued or undervalued right now?
Verde Science, Inc. (VRCI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VRCI before investing?
Before investing in Verde Science, Inc. (VRCI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Verde Science, Inc.
- OTC listing and lack of financial disclosure increase investment risk.